JP2023119042A5 - - Google Patents

Download PDF

Info

Publication number
JP2023119042A5
JP2023119042A5 JP2023113057A JP2023113057A JP2023119042A5 JP 2023119042 A5 JP2023119042 A5 JP 2023119042A5 JP 2023113057 A JP2023113057 A JP 2023113057A JP 2023113057 A JP2023113057 A JP 2023113057A JP 2023119042 A5 JP2023119042 A5 JP 2023119042A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
compound
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023113057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023119042A (ja
JP7689160B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2018/067306 external-priority patent/WO2019126761A1/en
Application filed filed Critical
Publication of JP2023119042A publication Critical patent/JP2023119042A/ja
Priority to JP2025034943A priority Critical patent/JP2025078783A/ja
Publication of JP2023119042A5 publication Critical patent/JP2023119042A5/ja
Application granted granted Critical
Publication of JP7689160B2 publication Critical patent/JP7689160B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023113057A 2017-12-22 2023-07-10 Ｃｎｓ障害の処置のための組成物および方法 Active JP7689160B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025034943A JP2025078783A (ja) 2017-12-22 2025-03-05 Ｃｎｓ障害の処置のための組成物および方法

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US201762610067P 2017-12-22 2017-12-22
US62/610,067 2017-12-22
US201762612070P 2017-12-29 2017-12-29
US201762611977P 2017-12-29 2017-12-29
US201762612164P 2017-12-29 2017-12-29
US201762612067P 2017-12-29 2017-12-29
US62/611,977 2017-12-29
US62/612,067 2017-12-29
US62/612,164 2017-12-29
US62/612,070 2017-12-29
US201862765164P 2018-08-17 2018-08-17
US62/765,164 2018-08-17
US201862728499P 2018-09-07 2018-09-07
US62/728,499 2018-09-07
US201862737559P 2018-09-27 2018-09-27
US62/737,559 2018-09-27
US201862754977P 2018-11-02 2018-11-02
US62/754,977 2018-11-02
PCT/US2018/067306 WO2019126761A1 (en) 2017-12-22 2018-12-21 Compositions and methods for treating cns disorders
JP2020534302A JP2021506904A (ja) 2017-12-22 2018-12-21 Ｃｎｓ障害の処置のための組成物および方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020534302A Division JP2021506904A (ja) 2017-12-22 2018-12-21 Ｃｎｓ障害の処置のための組成物および方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025034943A Division JP2025078783A (ja) 2017-12-22 2025-03-05 Ｃｎｓ障害の処置のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2023119042A JP2023119042A (ja) 2023-08-25
JP2023119042A5 true JP2023119042A5 (https=) 2025-03-14
JP7689160B2 JP7689160B2 (ja) 2025-06-05

Family

ID=65234664

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020534302A Withdrawn JP2021506904A (ja) 2017-12-22 2018-12-21 Ｃｎｓ障害の処置のための組成物および方法
JP2023113057A Active JP7689160B2 (ja) 2017-12-22 2023-07-10 Ｃｎｓ障害の処置のための組成物および方法
JP2025034943A Pending JP2025078783A (ja) 2017-12-22 2025-03-05 Ｃｎｓ障害の処置のための組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020534302A Withdrawn JP2021506904A (ja) 2017-12-22 2018-12-21 Ｃｎｓ障害の処置のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025034943A Pending JP2025078783A (ja) 2017-12-22 2025-03-05 Ｃｎｓ障害の処置のための組成物および方法

Country Status (14)

Country Link
US (2) US20220315621A1 (https=)
EP (1) EP3728285B1 (https=)
JP (3) JP2021506904A (https=)
KR (1) KR20200104349A (https=)
CN (3) CN118085004A (https=)
AR (1) AR114044A1 (https=)
AU (2) AU2018392093B2 (https=)
BR (1) BR112020012761A2 (https=)
CA (1) CA3086189A1 (https=)
IL (2) IL275506A (https=)
MA (1) MA51316A (https=)
MX (3) MX2020006608A (https=)
TW (1) TWI907333B (https=)
WO (1) WO2019126761A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2806877B2 (en) 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
BR112020012761A2 (pt) 2017-12-22 2021-02-17 Sage Therapeutics, Inc. composições e métodos para o tratamento de distúrbios do snc
TW201930269A (zh) 2018-01-12 2019-08-01 美商賽吉醫療公司 用於治療cns病症之組合物及方法
EP3750909B1 (en) * 2018-02-11 2025-03-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Steroid derivative regulators, method for preparing the same, and uses thereof
EP4321519B1 (en) 2018-10-12 2026-04-08 Sage Therapeutics, LLC Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
KR20250174100A (ko) 2018-12-05 2025-12-11 세이지 테라퓨틱스, 인크. 신경활성 스테로이드 및 이의 사용 방법
CN115651054B (zh) * 2019-01-08 2024-06-21 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
SG11202112391UA (en) 2019-05-31 2021-12-30 Sage Therapeutics Inc Neuroactive steroids and compositions thereof
JP7754725B2 (ja) * 2019-06-27 2025-10-15 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を治療するための組成物及び方法
CN114729000A (zh) * 2019-06-27 2022-07-08 萨奇治疗股份有限公司 用于治疗cns病症的化合物
CA3143509A1 (en) * 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
WO2022246634A1 (en) * 2021-05-25 2022-12-01 Zhejiang Jiachi Development Pharmaceuticals Ltd. Compositions for treating insomnia and uses thereof
WO2025016311A1 (zh) * 2023-07-14 2025-01-23 成都康弘药业集团股份有限公司 一种甾体类化合物的晶型及其用途
CN119529013B (zh) * 2024-11-25 2025-11-07 湖南新合新生物医药有限公司 一种祖拉诺龙中间体的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1380246A (en) * 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy-androstanes and esters thereof
ES432106A1 (es) * 1973-11-30 1976-11-01 Schering Ag Procedimiento para la preparacion de d-homo-20-cetopregna- nos.
DE2445161A1 (de) * 1974-09-19 1976-04-01 Schering Ag D-homo-20-ketopregnane ii
IL48628A0 (en) * 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
GB1570394A (en) * 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
GB1581234A (en) * 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
GB1581235A (en) * 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US5028631A (en) 1987-11-25 1991-07-02 Schwartz Arthur G Homoandrostan-17-one and homoandrosten-17-ones
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
CN1067976C (zh) 1994-12-03 2001-07-04 东国制药株式会社 积雪草酸衍生物及其制备方法和包含该衍生物的皮科制剂
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US6689767B2 (en) 2000-09-29 2004-02-10 Regents Of The University Of Minnesota Triterpenes having antibacterial activity
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
CN117024501A (zh) * 2014-10-16 2023-11-10 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
BR112020012761A2 (pt) 2017-12-22 2021-02-17 Sage Therapeutics, Inc. composições e métodos para o tratamento de distúrbios do snc
CN115651054B (zh) 2019-01-08 2024-06-21 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
JP7754725B2 (ja) 2019-06-27 2025-10-15 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を治療するための組成物及び方法

Similar Documents

Publication Publication Date Title
JP2023119042A5 (https=)
JP6933770B2 (ja) Ｈｉｖカプシド阻害剤のコリン塩形態
JP2021510695A5 (https=)
ES2660831T3 (es) Derivados de imidazol condensados útiles como inhibidores de IDO
JP2018505898A5 (https=)
WO2019023145A1 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
JP2022505841A5 (https=)
JP2017531020A5 (https=)
CA2972014A1 (en) Fused pyrimidine compounds for the treatment of hiv
AU2010308306A1 (en) Combination cancer therapy with HSP90 inhibitory compounds
JP2014524472A5 (https=)
JP2016517851A5 (https=)
KR20070107131A (ko) 증식성 장애의 치료를 위한 화합물
RU2008152763A (ru) Применение агонистов каннабиноидного рецептора в качестве индуцирующих гипотермию лекарственных средств для лечения ишемии
KR20160085917A (ko) 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
JP2022504607A5 (https=)
RU2010154173A (ru) Режим введения нитрокатехолов
JP2019515909A (ja) 慢性リンパ性白血病の治療を目的とするｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との配合物
RU2014139825A (ru) Производные ингенола для реактивации латентного вируса вич
JP2022548247A5 (https=)
CA2415577A1 (en) Use of cox-2 inhibitors for preventing immunodeficiency
JP2005515976A5 (https=)
JP2020500868A5 (https=)
RU2016133336A (ru) Новые производные CYP-эйкозаноидов
RU2019111188A (ru) Кетоновые ингибиторы лизин-специфичного гингипаина